DOJ escalates healthcare fraud enforcement, warns executives against Theranos-style deception

At the STAT Summit, DOJ officials signaled intensified scrutiny of healthcare executives, explicitly invoking the Theranos case as a cautionary tale. This marks a continued but sharpened enforcement posture, with implications for compliance costs and legal risk across the sector. The warning is rhetorical at this stage, with no new policy or case announced.